# First-line Replacement Maintenance of Envafolimab in Advanced NSCLC

> **NCT05465733** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 25 (estimated)

## Conditions studied

- Non-Small-Cell Lung

## Interventions

- **DRUG:** Envafolimab;Pemetrexed

## Key facts

- **NCT ID:** NCT05465733
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05465733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05465733, "First-line Replacement Maintenance of Envafolimab in Advanced NSCLC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05465733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*